Interview of patients with HR+/HER2- metastatic breast cancer who received capivasertib + fulvestrant

Inclusion Criteria

• Inclusion criteria (self-reported):
• - Adult (over the age of 18 years)
• - Diagnosed with HR+/HER2- metastatic breast cancer
• - Received at least 1 week of capivasertib + fulvestrant (Patients will be invited to provide documents demonstrating the use of capivasertib. Patients will be able to participate even if unable to obtain such documentation)
• Exclusion criteria (self-reported):
• - Patients who had discontinued capivasertib for more than 6 months before the date of the interview
• - Unable or unwilling to follow study procedures (including providing informed consent)
• - Not proficient in spoken English, as assessed by the moderator
• - Receiving capivasertib in a clinical trial setting
• - Patients who are not able to recall instruction for administration of capivasertib in a manner consistent with the labeling (e.g. 4 days on followed by 3 days off)